<DOC>
	<DOCNO>NCT01200732</DOCNO>
	<brief_summary>A preliminary observational study investigator show tadalafil , selective phosphodiesterase-5 inhibitor ( PDE-5 ) decrease pulmonary vascular resistance ( PVR ) patient eisenmenger syndrome ( ES ) result increase pulmonary blood flow ( Qp ) , systemic oxygen saturation ( SaO2 ) , functional class exercise capacity . The aim placebo control trial ass effect drug exercise capacity functional class compare placebo .</brief_summary>
	<brief_title>Phosphodiesterase-5 Inhibitor Eisenmenger Syndrome</brief_title>
	<detailed_description>Methods Patients ES age great equal 18 year weight great equal 30 kg World Health Organisation ( WHO ) functional class II III attend congenital clinic invite participate study . Informed write consent take patient screen procedure initiate study . A detailed clinical examination non-invasive test include electrocardiogram , chest X ray , pulmonary function test ( exclude associate restrictive/obstructive lung disease ) echocardiography ( include contrast echo require demonstrate right left shunt ) conduct . Patients simple congenital heart defect ( atrial septal defect &gt; 2cm , ventricular septal defect &gt; 1cm aortopulmonary communication &gt; 0.4 cm ) echocardiographic evidence right leave shunt include . Medical therapy clinical condition patient stable 3 month prior screen . Patients treatment prostanoids , endothelial receptor antagonist ( ERA ) , PDE-5 inhibitor vasodilator 1month prior screening exclude . A systemic pulse oximetry ( SpO2 ) 70 % 90 % rest room air baseline 6 minute walk test ( 6MWT ) distance 150 450 meter require inclusion . Eisenmenger physiology confirm cardiac catheterization mean pulmonary artery pressure &gt; 40mmHg , pulmonary capillary wedge pressure &lt; 15mmHg pulmonary vascular resistance &gt; 10 wood units/m2 . Oxygen study also do select patient diagnose reversible pulmonary arterial hypertension ( PAH ) patient exclude . Patients also exclude WHO class IV , congestive heart failure PCWP &gt; 15mmHg , leave ventricular ejection fraction &lt; 40 % , atrial fibrillation , patent ductus arteriosus , complex congenital heart defect , restrictive lung disease ( total lung capacity &lt; 70 % predict ) , obstructive lung disease ( forced expiratory volume 1 second [ FEV1 ] &lt; 70 % predict FEV1/ Forced vital capacity [ FVC ] &lt; 60 % ) , previously diagnose coronary artery disease require nitrate therapy , abnormal biochemical profile hypersensitivity PDE- 5 inhibitor . Left right heart catheterization do eligible patient describe preliminary observational study . Calculation pulmonary systemic blood flow ( Qs ) , PVR SVR perform use Ficks equation assume value oxygen consumption accord age gender patient . The study conduct accord recent amendment Declaration Helsinki adherence good clinical practice guideline . The trial approve National Drug Regulatory Authority ( DCG ) ethical committee institution . Study design procedure : A double blind randomise placebo control crossover trial carry study efficacy safety oral tadalafil . Eligible patient randomise receive either oral tadalafil match placebo baseline assessment WHO functional class , exercise capacity 6MWT hemodynamic study cardiac catheterization . Randomisation , blind drug/placebo administration do two pharmacist hospital . Patients receive tadalafil 40mg daily match placebo 6 week follow 2 week washout cross drug another 6 week . Routine medication PAH like digoxin diuretic continue study . Compliance assess pill count method 3 weekly interval . Safety drug placebo assess noting adverse effect , vital sign ( SaO2 ) pulse oximetry 3 week interval . Clinical assessment ( WHO functional class ) , 6 MWT hemodynamic parameter cardiac catheterization reassess 6 week end study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Patients ES age great equal 14 year weight great equal 30 kg World Health Organisation ( WHO ) functional class II III attend congenital clinic invite participate study WHO class IV , congestive heart failure PCWP &gt; 15mmHg , leave ventricular ejection fraction &lt; 40 % , atrial fibrillation , patent ductus arteriosus , complex congenital heart defect , restrictive lung disease ( total lung capacity &lt; 70 % predict ) , obstructive lung disease ( forced expiratory volume 1 second [ FEV1 ] &lt; 70 % predict FEV1/ Forced vital capacity [ FVC ] &lt; 60 % ) , previously diagnose coronary artery disease require nitrate therapy , abnormal biochemical profile hypersensitivity PDE 5 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Tadalafil</keyword>
	<keyword>phosphodiesterase-5 inhibitor</keyword>
	<keyword>Eisenmenger syndrome</keyword>
</DOC>